齐拉西酮合并丁螺环酮治疗精神分裂症的对照研究(1)
 |
| 第1页 |
参见附件(1911KB，2页)。
[摘要] 目的：探讨齐拉西酮合并丁螺环酮治疗精神分裂症的疗效和安全性。方法：将112例符合CCMD-3诊断标准的精神分裂症患者随机均分为两组，研究组给予齐拉西酮合并丁螺环酮治疗，对照组单独给予齐拉西酮治疗，疗程8周。分别于治疗前和治疗后2、4、6、8周末采用阳性症状和阴性症状量表(PANSS)评定临床疗效，副反应量表(TESS)评定副反应。结果：治疗8周后，研究组和对照组的有效率差异无统计学意义(P>0.05)；对照组的副反应心动过速、锥体外系反应、静坐不能发生率显著高于研究组(P<0.05)。结论：齐拉西酮合并丁螺环酮治疗精神分裂症患者的疗效较好，副作用较小，值得推广。
[关键词] 齐拉西酮；丁螺环酮；精神分裂症；疗效
[中图分类号] R971+.41 [文献标识码]B[文章编号]1674-4721(2011)04(c)-071-02
Contrast study of ziprasidone combined with buspirone in treatment of schizophrenia
LI Yuchun, FENG Yanguo, DU Yunhong, ZHANG Zhiyong, CHENG Dejun
The Second Affiliated Hospital of Xinxiang Medical College, Henan Province, Xinxiang 453002, China
[Abstract] Objective: To study the efficacy and safety of ziprasidone combined with buspirone in the treatment of schizophrenia. Methods: 112 patients with schizophrenia by CCMD-3 were randomly allocated to treatment group and control group, treated respectively with ziprasidone combined with buspirone or with ziprasidone alone for 8 weeks. The PANSS and TESS were employed to evaluate the efficacy and adverse effects respectively before and at the ends of 2, 4, 6, and 8 weeks′ treatment. Results: The total effective rates for the treatment group and control group were similar after the 8-week treatment. There was no significant difference between the two groups. Incidence of adverse effects, such as tachycardia, extrapyramidal reactions and akathisia, was significantly lower in the treatment group than in the control group(P<0.05). Conclusion: Ziprasidone combined with buspirone has similar efficacy but fewer side effects in the treatment of schizophrenia.
[Key words] Ziprasidone; Buspirone; Schizophrenia; Efficacy
为探讨齐拉西酮合并丁螺环酮治疗精神分裂症患者的疗效及安全性，2009年6月～2010年6月笔者以单用齐拉西酮治疗作为对照，比较两组之间的疗效与安全性，以期能更好地指导日常临床工作，现报道如下：
1 资料与方法
1.1 一般资料
112例患者均为河南省精神病医院住院治疗的精神分裂症患者，所用患者入组前均获得知情同意。研究药物均为江苏恩华药业股份有限公司生产，齐拉西酮商品名：思贝格，丁螺环酮商品名：一舒。将其随机均分为研究组和对照组各56例，所有入组患者均符合中国精神障碍分类与诊断标准第3版(CCMD-3)精神分裂症的诊断标准，年龄为18~65岁，PANSS量表[1]评分≥60分。入院前1周内没有使用抗精神病药物且1个月内没有使用长效抗精神病药物。排除躯体和脑器质性疾病者、酒精滥用和药物依赖者、妊娠或哺乳妇女及有严重的攻击行为或自杀企图者。研究组：有2例因恶心、呕吐退出研究，实际完成54例，其中，男30例，女24例，年龄18~58岁，平均(27.2±12.3)岁，病程(11.5±3 ......
您现在查看是摘要介绍页，详见PDF附件(1911KB，2页)。